Immunotherapy represents a transformative strategy in oncology, aiming to empower the patient’s immune system to recognize and eradicate cancer cells. However, despite remarkable successes, a significant subset of patients exhibits resistance or suboptimal responses. The Karolinska team sought to decipher the cellular dynamics that contribute to these varied outcomes, centering their investigations on neutrophils within two distinct murine cancer models: melanoma and breast carcinoma. These granulocytes, although frontline defenders against pathogens, exhibit complex, often paradoxical, behavior in malignancies.

By employing genetically engineered mice completely lacking neutrophils, researchers created a fundamental contrast with normal counterparts possessing intact neutrophil populations. Remarkably, the absence of neutrophils was associated with amplified effectiveness of multiple immunotherapeutic modalities. Tumor volumes decreased more significantly, paralleled by an influx and heightened activation of cytotoxic T lymphocytes (CTLs) within the tumor niche. This phenomenon underscores a previously underappreciated suppressive influence neutrophils exert over the adaptive immune response prompted by therapy.

Delving deeper, the study elucidates a sophisticated feedback mechanism involving neutrophils and tumor signaling pathways. Following the initiation of immunotherapy, neutrophils themselves undergo a phenotypic modulation wherein they begin expressing programmed death-ligand 1 (PD-L1). PD-L1 is a critical immune checkpoint molecule that suppresses T cell-mediated tumor clearance by binding to PD-1 receptors on T cells, thereby attenuating their cytotoxic functions. This induction of PD-L1 expression on neutrophils is driven by interferon-gamma (IFN-γ), a type II interferon secreted by activated immune cells within the tumor milieu.

Crucially, when the research team selectively ablated PD-L1 or disrupted the IFN-γ receptor specifically on neutrophils, immunotherapeutic efficacy was restored to greater degrees. This compelling evidence demonstrates that the tumor microenvironment dynamically instructs neutrophils to adopt immune checkpoint properties that blunt T cell activity. Such findings challenge the prevailing conception of neutrophils as mere innate immune effectors and highlight their role as modulators of adaptive immune resistance in cancer.

The implications of this discovery are far-reaching. It establishes that the neutrophil response to cancer immunotherapy is not a static trait but is governed by extrinsic signals within the tumor’s immunological landscape. Consequently, therapeutic strategies that target neutrophil-mediated inhibition hold promise to synergize with existing immunotherapies, potentially overcoming resistance and refining treatment responses. This conceptual pivot points toward the development of combination therapies integrating immune checkpoint blockade with interventions designed to neutralize neutrophil-driven suppression.

Moreover, the translational relevance of the study is underscored by observations from human tumor samples. Analysis of specimens from lung cancer patients undergoing immunotherapy revealed similar neutrophil PD-L1 expression patterns, hinting that the interplay observed in murine models reflects conserved phenomena in human malignancies. This cross-species validation bolsters the clinical significance of targeting neutrophil-mediated pathways to augment immunotherapy outcomes.

These insights also invite a broader reconsideration of the tumor microenvironment’s composition and the intricate crosstalk among immune cell subsets. Neutrophils, once relegated to simple categorizations of pro-inflammatory or anti-inflammatory cells, are now appreciated as plastic entities capable of both promoting and suppressing tumor progression, contingent upon microenvironmental cues. The dynamic induction of inhibitory molecules such as PD-L1 represents a striking example of how tumors can hijack immune cells to construct barriers against eradication.

The study was the result of an international collaboration, bringing together expertise from institutions across Sweden, the United States, Germany, and China. Supported by funding from major agencies including the National Institutes of Health, the Swedish Cancer Society, and the Swedish Foundation for Strategic Research, the comprehensive nature of the research reflects a global commitment to advancing cancer immunology. Importantly, the investigators have declared no conflicts of interest, adding credibility to their groundbreaking conclusions.

In practical terms, these findings suggest that future cancer treatment regimens may need to incorporate strategies that either deplete neutrophils or inhibit their PD-L1 induction to unleash maximal T cell function. Such approaches could involve novel pharmacological inhibitors, antibody-based therapies against neutrophil-expressed PD-L1, or modulation of IFN-γ signaling pathways. The goal is to dismantle the immunosuppressive barricades within tumors that limit the curative potential of current immunotherapies.

Ultimately, this research deepens our understanding of the immune landscape in cancer and highlights the nuanced roles played by different leukocyte populations. It emphasizes the importance of a systems biology approach to cancer therapy, where combinatorial treatments targeting multiple cellular and molecular mechanisms stand a better chance of success. As immunotherapy continues to revolutionize cancer care, dissecting the multifaceted interactions within the tumor milieu remains paramount for overcoming resistance and achieving durable remissions.

The Karolinska Institutet study encapsulates a pivotal moment in cancer immunology—recognizing neutrophils not just as effectors but also as modulators of immune evasion. Such nuanced insights will undoubtedly steer the field towards more sophisticated, rationally designed therapies, paving the way for improved patient outcomes in the battle against cancer.

Subject of Research: Neutrophil regulation in cancer immunotherapy through type II interferon signaling.

Article Title: Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon

News Publication Date: 15 June 2026

Web References: https://doi.org/10.1016/j.immuni.2026.05.014

References: Shengduo Pei, Yueyun Pan, Heng Liang, Li Lei, Qirong Lin, Jiarui Mi, Jeffrey V Ravetch, Oliver Soehnlein, Mikael C.I. Karlsson, Immunity, 15 June 2026.

Keywords: Cancer, Immunotherapy, Neutrophils, PD-L1, Interferon-gamma, Tumor microenvironment, T cells, Immune checkpoints, Immunosuppression, Leukocytes, Granulocytes, Tumor resistance

Breast cancer remains the second leading cause of cancer-related mortality among American women, with metastasis accounting for over 90% of fatalities. Despite advancements in therapeutic regimens, the complete landscape of molecular drivers fueling breast cancer dissemination and resistance to treatments has remained elusive. Nelson’s team has now made a pivotal contribution toward filling this critical knowledge gap by spotlighting the role of cholesterol metabolites in modulating tumor-immune interactions.

Building on prior epidemiological associations linking elevated cholesterol levels with adverse breast cancer outcomes, Nelson’s laboratory utilized sophisticated preclinical animal models to focus on a specific cholesterol derivative: 27-hydroxycholesterol (27HC). Their research delineates how 27HC orchestrates immune evasion mechanisms by modulating neutrophil behavior, fundamentally altering the immune system’s capacity to target and eliminate cancer cells. Neutrophils, a frontline immune cell subset, respond to 27HC by secreting extracellular vesicles (EVs), small membrane-bound particles that serve as potent intercellular communicators.

Delving deeper into the mechanistic underpinnings, the team uncovered that these neutrophil-derived EVs convey pro-tumorigenic signals to breast cancer cells, effectively reprogramming them toward a more aggressive phenotype. This communication axis actively promotes epithelial-mesenchymal transition (EMT), a cellular process where epithelial tumor cells acquire migratory, invasive, and stem-like characteristics, thereby enhancing metastatic potential and chemotherapy resistance. Such findings delineate how 27HC facilitates a microenvironment conducive to cancer progression by hijacking immune cell communication modalities.

The study, recently published in Cancer Letters, marks a significant advancement in our understanding of tumor-immune system crosstalk mediated through extracellular vesicles. First author Natalia Krawczynska elaborates on their discovery: “27HC instructs neutrophils to customize the cargo of secreted EVs, which subsequently interact with cancer cells, inducing transcriptional and phenotypic changes that endow them with stemness and chemoresistance.” These insights elevate the biological importance of EVs as not merely cellular debris but as sophisticated vehicles orchestrating cancer dynamics.

Erik Nelson emphasizes the translational potential of these findings: “By interrupting this neutrophil EV messaging system, we can sensitize metastatic breast cancer cells to existing chemotherapies, potentially improving patient outcomes.” This concept heralds a paradigm shift, suggesting that therapeutic strategies targeting EV-mediated communication could complement and potentiate current treatment modalities.

Looking forward, Nelson’s team aims to pioneer novel intervention strategies that disrupt the early-stage dialogue between neutrophil EVs and cancer cells. Early therapeutic blockade of this axis could reduce the incidence of metastatic spread, which remains the principal cause of breast cancer lethality. The laboratory plans to pursue high-throughput screening of available pharmacological agents and collaborate with chemists to engineer new compounds capable of modulating EV biogenesis and cargo composition.

Furthermore, the lab is exploring the influence of diet, pharmacological agents, and host biological factors on the neutrophil EV signaling network. Understanding how lifestyle and systemic variables impact this microenvironmental conversation could reveal adjunctive modalities to prevent cancer progression. The researchers also hypothesize that neutrophil EVs might exert multifaceted effects on other stromal and immune constituents within the tumor microenvironment, propagating a complex ‘telephone game’ of signals that collectively drive malignancy.

This multi-pronged research endeavor leverages the interdisciplinary expertise converging at the Cancer Center at Illinois, uniting biologists, bioengineers, chemists, and computational scientists in pursuit of comprehensive elucidation and therapeutic targeting of EV-mediated communication. The center’s collaborative ethos and technological resources position it uniquely to translate these molecular insights into clinical innovations.

In addition to preclinical exploration, Nelson’s lab is setting the stage for clinical collaborations aimed at evaluating the prognostic potential of circulating neutrophil EVs in breast cancer patients. Monitoring EV profiles in patient blood samples could serve as an early biomarker for metastatic relapse, enabling preemptive intervention strategies tailored to individual disease trajectories and enhancing personalized medicine approaches.

Crucially, the team demonstrated that neutralizing the ‘message’ encoded by 27HC-exposed neutrophil EVs can reverse the malignant phenotype, restoring sensitivity to chemotherapy and reducing metastatic competency. This proof-of-concept establishes a tangible target for future drug development and clinical trials, highlighting the therapeutic viability of disrupting immune cell-tumor communication vectors.

The implications of this research extend beyond breast cancer, as EVs are emerging as universal mediators in various cancer types and immune-related diseases. These findings not only deepen our molecular understanding of cancer biology but also inspire a novel class of interventions harnessing the modulation of immune-derived extracellular vesicles to combat metastasis and therapeutic resistance.

Overall, Erik Nelson and his colleagues have unveiled a sophisticated molecular mechanism by which a cholesterol metabolite manipulates immune surveillance to exacerbate breast cancer progression. Their work bridges fundamental immunology, cancer biology, and translational research, providing a foundation for innovative strategies to undermine tumor resilience and improve patient prognosis in the ongoing battle against breast cancer.

Subject of Research: The molecular mechanisms by which cholesterol metabolites, particularly 27-hydroxycholesterol (27HC), influence neutrophil extracellular vesicle secretion and the subsequent promotion of epithelial-mesenchymal transition and stemness in breast cancer cells, leading to enhanced metastasis and chemotherapy resistance.

Article Title: Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells

News Publication Date: 28 October 2025

Web References:
https://www.sciencedirect.com/science/article/pii/S0304383525006779
http://dx.doi.org/10.1016/j.canlet.2025.218105

Keywords: Cancer, Breast cancer, Metastasis

Neutrophils, the most abundant type of white blood cells, execute their defense mechanisms not only through phagocytosis and degranulation but also by ejecting NETs. This aggressive mode of action traps and neutralizes invading pathogens. However, cancer cells exploit this mechanism, hijacking the NET formation process to facilitate their own survival and dissemination. The intricate dance between tumor cells and neutrophils culminates in a pathological cycle where NETs create a pro-tumorigenic niche. This discovery has led researchers to delve deeper into the molecular cascades triggering NETosis—the process of NET formation—in cancerous settings, revealing an elaborate network of signaling molecules and cellular interactions that drive this phenomenon.

Recent breakthroughs have highlighted key molecular players that mediate NETosis in cancer. Reactive oxygen species (ROS), enzyme effectors like neutrophil elastase (NE), and peptidylarginine deiminase 4 (PAD4) emerge as central orchestrators of chromatin decondensation and release in neutrophils. The tumor microenvironment often presents oxidative stress, inflammatory cytokines, and chemokines that induce these pathways, pushing neutrophils toward NET formation. Precisely how these signaling axes differ between physiological immune responses and pathological cancer contexts continues to churn as an active area of research. Understanding this distinction is paramount for therapeutic targeting that minimizes damage to normal immune functions.

Moreover, researchers have elucidated that NETs act as physical and biochemical scaffolds within tumors, capturing circulating tumor cells and facilitating metastatic seeding at distant organs. This entrapment effect significantly contributes to cancer spread, a primary cause of mortality among patients. Investigations into the structural composition of NETs reveal a rich milieu of proteases and cytokines tethered to the chromatin matrix, which collectively remodel the extracellular environment. Such remodeling influences tumor cell adhesion, survival, and evasion of immune surveillance. This dualistic role of NETs—as defenders in infections and inadvertent accomplices in cancer progression—encapsulates the complexity of immune regulation within oncogenic processes.

The involvement of NETs also extends to resistance mechanisms against conventional cancer therapies. Studies suggest that NETs induce a physical barrier limiting the penetration of chemotherapeutic agents, thereby dampening treatment efficacy. Furthermore, components of NETs may activate survival pathways in tumor cells, rendering them more resilient to apoptosis induced by drugs or radiation. These insights open new avenues for designing adjunct therapies that disrupt NET formation or facilitate their degradation to sensitize tumors to existing treatments. Targeted inhibition of PAD4 or use of DNase enzymes to dismantle the NET framework has gained traction as promising strategies in preclinical models.

Interdisciplinary research utilizing advanced imaging techniques, proteomics, and genetic models has been pivotal in mapping NET formation and function in vivo. Fluorescent microscopy coupled with intravital imaging provides real-time visualization of NETs within tumors and metastatic niches, revealing spatial and temporal dynamics previously inaccessible. Mass spectrometry-based proteomic profiling uncovers the diverse array of proteins bound to NETs, offering a comprehensive view of their biochemical signature. Genetic knockout models of PAD4 or NE help delineate the consequences of disrupted NETosis on tumor progression, reinforcing the critical nature of these enzymes. This integrative approach accelerates the translation of fundamental mechanistic knowledge into clinically actionable interventions.

Additionally, the crosstalk between NETs and other immune cells adds an extra layer of complexity to tumor immunity. NET-associated proteins modulate the activity of macrophages, dendritic cells, and lymphocytes, influencing their phenotype and function within the cancer milieu. For example, NETs may skew macrophages toward a tumor-promoting M2 phenotype or suppress cytotoxic T cell responses, tipping the immunological balance in favor of tumor survival. These immunomodulatory effects help explain why tumors with abundant NET presence often correlate with poor prognosis. Capturing these interactions opens a window for immunotherapeutic modulation, aiming to restore effective anti-tumor immunity.

Beyond primary tumors, NETs have been implicated in cancer-associated thrombosis, a serious complication that worsens patient outcomes. NETs provide a scaffold for platelet adhesion and fibrin deposition, triggering thrombus formation within blood vessels. This prothrombotic environment exacerbates tumor burden and increases mortality risks due to embolic events. Insights into how cancer escalates NET-mediated thrombosis have propelled investigations into anticoagulant therapies that also target NET structure or formation, presenting dual benefits. This connection highlights the broad systemic impact of NETs in cancer pathology, extending well beyond localized tumor growth.

Clinical correlations further underscore the significance of NET biology in cancer prognosis and diagnosis. Elevated circulating levels of NET components serve as biomarkers predictive of metastasis and survival rates across multiple cancer types including lung, breast, and pancreatic cancers. The quantification of these markers in patient blood samples offers a minimally invasive tool for disease monitoring and therapeutic response assessment. Future research aims to refine such biomarker panels and integrate them into precision medicine frameworks. This translational aspect cements NET research not only as a basic science triumph but also as a driver of improved patient care.

Exploring pharmacological inhibitors that specifically target NET formation is rapidly gaining momentum. Several small molecules and biologics that hinder PAD4 activity, ROS production, or enzymatic release from neutrophils show promising anticancer potential. Early-stage clinical trials are underway to assess their safety and efficacy, marking a hopeful horizon for adjunctive therapies. Additionally, combinational regimens incorporating NET inhibitors with immunotherapies, chemotherapy, or targeted agents are under exploration to maximize therapeutic outcomes. The prospect of disrupting a fundamental tumor-supportive mechanism without broadly suppressing immunity offers a highly attractive therapeutic window.

The heterogeneity of NET formation in different cancer types and stages suggests that personalized approaches may be necessary. Tumor genetics, microenvironmental cues, and patient immune status collectively influence how NETosis is regulated. Deciphering these context-dependent variables requires large-scale integrative studies encompassing genomics, proteomics, and immune profiling. This will enable stratification of patients who might benefit most from NET-targeted interventions and avoid unintended immune compromise. Such precision medicine paradigms are becoming an essential aspect of modern oncology.

Excitingly, the study of NETs intersects with emerging fields such as cancer metabolism and epigenetics. Metabolic alterations within neutrophils affect their capacity for NET release, while epigenetic modifications regulate the expression of enzymes critical for NETosis. These discoveries provide novel checkpoints for intervention and hint at broader systemic changes that accompany oncogenesis. By incorporating metabolic and epigenetic dimensions into the understanding of NET biology, scientists hope to unearth multifaceted targets that simultaneously disrupt tumor support and enhance immune function.

Ethical considerations and safety remain paramount as NET-directed therapies advance toward clinical application. Given the indispensable role of neutrophils in infection control, therapies must be carefully designed to avoid predisposing patients to opportunistic infections. Balancing effective suppression of pathological NETs with preservation of host defense mechanisms is a delicate endeavor. Ongoing and future clinical studies will need to vigilantly monitor adverse effects while validating therapeutic benefits. The evolving field of cancer immunology stands ready to embrace these challenges while applying innovative biological insights.

In conclusion, the expanding mechanistic understanding of NET formation in cancer has revolutionized perspectives on tumor-immune interactions and opened new therapeutic frontiers. From molecular underpinnings and immune modulation to clinical implications and drug development, research is rapidly unraveling the complex roles that NETs play in malignancy. The intricate balance between their protective and pathological functions underscores the sophistication of immune-tumor crosstalk. As the science advances, integrating NET biology into comprehensive cancer care promises to improve outcomes and offer hope for patients facing the devastating consequences of cancer metastasis.

Subject of Research: Mechanistic understanding of neutrophil extracellular traps (NETs) formation in cancer and their role in tumor progression and metastasis.

Article Title: Progress in the mechanistic understanding of NETs formation in cancer.

Article References:
Luo, C., Xiong, X., Fang, C. et al. Progress in the mechanistic understanding of NETs formation in cancer. Med Oncol 42, 451 (2025). https://doi.org/10.1007/s12032-025-03010-x

Image Credits: AI Generated